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Abstract 
 This article discusses the current techniques and future directions of infection 
imaging with particular attention to respiratory, CNS, abdominal, and postoperative 
infections.  The agents currently in use localize to areas of infection and inflammation.  
An infection specific imaging agent would greatly improve the utility of scintigraphy in 
imaging occult infections.  The superior spatial resolution of 18F-FDG PET and its lack of 
reliance on a functional immune system, gives this agent certain advantages over the 
other radiopharmaceuticals. 
 In respiratory infection imaging, an important advancement would be the ability 
to quantitatively delineate lung inflammation, allowing one to monitor the therapeutic 
response in a variety of conditions.  Current studies suggest PET should be considered 
the most accurate quantitative method.  
 Scintigraphy has much to offer in localizing abdominal infection as well as 
inflammation.  We may begin to see a gradual increase in the usage of FDG PET in 
detecting occult abdominal infections.  Commonly used modalities for imaging 
inflammatory bowel disease are scintigraphy with 111In-oxine/ 99mTc-HMPAO labeled 
autologous white blood cells. 
 The literature on CNS infection imaging is relatively scarce.  Few clinical studies 
have been performed and numerous new agents have been developed for this use with 
varying results. Further studies are needed to more clearly delineate the future direction 
of this field.    
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In evaluating the post-operative spine, 99mTc-ciprofloxacin SPECT was reported 
to be >80% sensitive in patients more than 6 months post-surgery.  FDG PET has also 
been suggested for this purpose and may play a larger role than originally thought.   
 It appears PET/CT is gaining support, especially in imaging those with fever of 
unknown origin or nonfunctional immune systems.  While an infection specific agent is 
lacking, the development of one would greatly advance our ability to detect, localize, and 
quantify infections.  Overall, imaging such an agent via SPECT/CT or PET/CT will pave 
the way for greater clinical reliability in the localization of infection. 
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The Development of Infection Specific Imaging Agents 
Since the advent of 67Ga citrate for routine infection imaging, a variety of agents 
have been developed and evaluated to better localize and detect areas of infection within 
the body.  There has certainly been some advancement since the introduction of 67Ga 
citrate in 1971, but a true infection-specific imaging agent has yet to be developed.  
Almost all of the commonly used imaging agents localize to areas of inflammation rather 
than specifically those of infection, which makes clinical interpretation difficult and at 
times unreliable, particularly when the infection requires aggressive therapeutic 
intervention. 
 Inflammation and infection are different processes.  Inflammation is merely a 
nonspecific immune response - one which does not require the presence of micro-
organisms to occur.  Inflammation can occur from trauma, ischemia, neoplasm, 
autoimmune attack, or invasion by micro-organisms.  Conversely, the presence of a locus 
of micro-organisms may not lead to inflammation in the immunocompromised patient, 
but still constitutes a site of infection.   It should be recognized that all 
radiopharmaceuticals accumulate to some extent in this quality due to inflammation at the 
site of infection (1, 2). 
Granulocytes play an important role in the pathophysiology of infections and the 
development of imaging agents concerning infections. There are 3 physiological 
compartments that are involved in the granulocyte kinetics: the circulating and 
marginating granulocytes which constitute the total blood pool, the granulocyte pool in 
the bone marrow responsible for the development and release of granulocytes and the 
pools within which the blood granulocytes are physiologically destroyed. The average 
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granulocyte residence time is 10 days and is replaced at a rate of 10 h. The hallmark of an 
infective process is enhanced vascular permeability, leading to the leakage of fluid and 
small molecules at the affected site and associated transudation or diapedesis of 
leukocytes leading to local accumulation of these cells. The process of migration of 
granulocytes from the second compartment towards the sites of infection is considered to 
be an important factor for targeting foci of infection (3).  Radiopharmaceuticals utilize 
these properties to localize the lesion.   It is for these reasons that the goal of developing 
an infection-specific imaging agent is a topic of much ongoing research.  In this article 
we will review the current progress of non-osseous infection imaging and discuss those 
agents that hold promise for further research and future clinical utility. 
 An advancement over the original 67Ga citrate infection imaging was the 
development of in vitro radiolabeled white blood cells (WBCs) using 111In-oxine (4) or 
99mTc-hexamethylpropylene amine oxime (99mTc-HMPAO).  The chemotactic properties 
of the activated leukocytes form the basis of labeled leukocyte imaging. The various 
problems encountered in leukocyte labeling are discussed in the next section. One 
disadvantage worth mentioning is the inability to differentiate infection related to urinary 
and gastrointestinal systems. Continued research in this field led to the development of 
labeled antibiotics. 99mTc-labeled ciprofloxacin was reported to bind to the DNA gyrase 
of living bacteria, thereby distinguishing bacterial infection from inflammation (5). The 
other agents which have found their place in infection imaging are ubiquicidin analogs 
which are chemotactic peptide fragments, and nonpeptide molecules, such as leukotriene 
antagonists which bind to the leukocytes (6, 7).  A newer technique that has recently 
gained favor in clinical use is that of Positron Emission Tomography – Computerized 
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Tomography (PET-CT)  imaging for the rapid detection and localization of occult 
infection.  18Fluoro-deoxy-glucose (18F-FDG) has been shown to target sites of infection 
via increased glucose utilization by infiltrated granulocytes and macrophages due to 
metabolic requirements.  However this is nonspecific since 18F-FDG is also taken up at 
non-specific sites of inflammation as well as sites of tumor (8).  The sensitivity of 18F-
FDG PET (FDG PET) in patients suspected with focal infection is reported to be similar 
to that of 111In-labeled leukocytes; however false-positive changes are seen in patients 
with malignancy and in the postoperative period leading to low specificity (9). 
 It is clear that as of now, an ideal infection imaging agent does not exist.  Table 1 
lists the current available strategies for developing these agents.  The generally accepted 
characteristics that constitute an ideal imaging agent are listed below.  The goal in 
development is to strive for an agent that comes as close as possible to meeting the 
following criteria:   
• Accumulation only in those areas of active infection.  Easily distinguishable from 
background uptake or low uptake in non-infected tissues. 
• Absence of physiological accumulation of the tracer in the blood and bone marrow, liver, 
spleen and rapid washout of background activity. 
• No adverse toxic effects and free of immune-reactions. 
• Safe, quick, and cost-effective preparation. 
• The ability of uptake at sites of infection in vivo, without requiring outside preparation 
and handling of blood products. 
• Low radiation burden to the patient. 
• Differentiation between infection and non-specific inflammation. 
• Rapid blood clearance and rapid accumulation at the site of infection. 
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<<TABLE 1>> 
 
Agents for Infection/Inflammation Imaging Currently in Clinical Use 
67Ga Citrate 
 Since 1971, 67Ga citrate has been used to detect infection and inflammation.  
Certain studies have suggested that following injection, the 67Ga citrate forms a complex 
with transferrin, and undergoes extravasation at the site of inflammation/infection.  The 
exact mechanism of retention in the infectious lesion is not entirely clarified, but data 
from various models support the role of bacterial siderophores and lactoferrin in 
leukocytes (10). 
 Discrimination of infection is difficult using 67Ga citrate due to the normal uptake 
that is found in the bowel, liver, spleen, bone and genitourinary system and its slow blood 
clearance.  Laxative administration can clear unwanted colonic activity, but is 
cumbersome and undesirable for the patient.  In addition, 67Ga citrate has unfavorable 
imaging characteristics (long physical half-life and a low abundance of high-energy 
gamma radiations), causing high-radiation absorbed doses and relatively poor image 
quality. Furthermore, optimal imaging often requires delayed imaging for up to 72 hours 
post-injection (10). 
 Figure 1 demonstrates a positive 67Ga citrate scan in a patient with Pneumocystis 
carinii (PCP) pneumonia.  Note the background uptake that occurs in the bowel, spleen, 
bone, and genitourinary tract.  This does not interfere with making a clear diagnosis of a 
respiratory infection in this case; however in other locations, it can make interpretation 
difficult or impossible. In addition, lactating women can have high background uptake in 
breast tissue, potentially interfering with respiratory tract imaging.   
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<<FIGURE 1>> 
 
Radiolabeled WBCs 
 Radiolabeled WBCs are the most commonly used method to detect and localize 
infection today.  The WBCs can be labeled using either 111In or 99mTc-
hexamethylpropylene amine oxime HMPAO.   McAfee and Thakur developed a 
technique to label autologous leukocytes with 111In by using oxinate as a chelator to 
transfer the tracer into the cell (10, 11).  Peters et al developed HMPAO, a lipophilic 
chelator that allows the efficient labeling of white blood cells with 99mTc.  Because of its 
more favorable radiation characteristics for imaging, 99mTc-HMPAO is more commonly 
used over 111In (2).  One drawback of 99m Tc-HMPAO, however, is that of in vivo tracer 
elution from labeled cells.  Also, the technique of WBC labeling is not without its own 
set of drawbacks.   First, there is the risk to health-care workers involved with the 
handling of blood products.  Secondly, there is a cost and time concern involved with the 
labeling of the WBCs.  Indeed, it typically can take up to 3-4 hours from phlebotomy to 
completion of injection.  In patients suffering from neutropenia there is difficulty 
associated with obtaining a sufficient amount of WBCs to label.  In addition to this, the 
functional status of the WBCs must also be taken into account.  Another concern involves 
patients receiving chemotherapy or other immune modulating agents that can affect WBC 
harvesting and/or function when injected back into the patient.  Therefore, patients 
undergoing chemotherapy, receiving glucocorticoids, or infected with HIV may be 
difficult or impossible to image.  The reported sensitivity and specificity for radiolabeled 
WBCs ranges from 86-90%, with a slightly higher sensitivity for acute infections likely 
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due to the increased granulocytic response (12).  This discovery was a significant 
advancement over the traditional 67Ga-citrate agent. Yet, WBCs are also able to localize 
to non-specific areas of inflammation and thus lack specificity for infection.  
Nonetheless, ex vivo labeling of leukocytes to 18F-FDG for 18F-FDG -WBC hybrid 
PET/CT imaging was found to detect foci of infection with high precision. 
 
Nonspecific Immunoglobulins 
 Nonspecific polyclonal human immunoglobulins have been shown to localize to 
sites of infection/inflammation by extravasation from the bloodstream due to the induced 
local hyperemia (13) and this agent is thus, nonspecific for infection.  One noteworthy 
benefit of this agent is that since it is derived from human antibodies, it negates the 
possibility of a Human Anti Murine Antibody (HAMA) response.  This agent can be 
labeled with either 111In or 99mTc and thus suffers from some of the limitations of 
biodistribution of these agents.  Studies have shown that detection of infection is reliable, 
but drawbacks include long-imaging time, and delayed blood-pool clearance.   It is 
uncertain if this agent will play a promising role in clinical utility, especially given the 
potentially harmful side effects of other previously studied labeled antibodies, and the 
promising results of other newer agents. 
 
PET Agents 
18F-FDG is known to accumulate at sites of infection, inflammation and in 
autoimmune and granulomatous diseases. The inflammatory cells produce an excess of 
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glycolytic enzymes and also overexpress glucose transporter (GLUT) isotypes (mainly 
GLUT-1 and GLUT-3) (14). 
FDG PET can diagnose a variety of infections with a fairly high degree of 
certainty.  Just a few examples include large-vessel vasculitis, abdominal infections such 
as inflammatory bowel disease, thoracic and soft-tissue infection. It is also useful in 
tumor induced fever, secondary to Hodgkin's disease, aggressive non-Hodgkin's 
lymphoma, colorectal cancer and sarcoma. In patients with fever of unknown origin 
(FUO), in vitro or in vivo labeled WBC
 
 methods are of limited value because of the rather 
low prevalence of granulocytic processes in this clinical setting (15).  
Various in vitro studies of 18F-FDG labeling of human leukocytes using mixed/ 
pure preparations of neutrophils and mononuclear cells have been reported.  Granulocyte 
uptake accounted for 78%–87% of the activity in mixed preparations. Labeling of WBCs 
with 18F-FDG was not stable and the labeling yield ranged from 40% to 80% when pure 
preparations of WBC were used. Neutrophils when stimulated for 60 min by N-formyl-
methionyl-leucyl-phenylalanine, a chemotactic peptide, revealed a significant increase in 
18F-FDG uptake (16-19). 
 
In vivo labeling of WBCs using antibodies or antibody fragments 
After the development of the above described techniques for labeling WBCs in 
vitro, the focus on discovery of an agent with the ability to label WBCs in vivo became an 
increasingly popular area of research.  This would eliminate many of the drawbacks to 
the techniques of in vitro labeling that are still in common practice today.  This would 
include a shorter preparation time, as well as elimination of the possible degradation in 
 12 
WBC function as a result of removal and re-injection into the body.  The first reported 
case of in vivo WBC labeling was performed by Locher et al. using radiolabeled 
monoclonal antibody (MoAb) in 1986. 
 To date, at least three antigranulocyte antibodies have been tested for infection 
imaging: anti-NCA-95 immunoglobulin G (IgG) (BW250/183), anti-NCA-90 Fab' 
(Immu-MN3, Leukoscan: anti-CD66 [Immunomedics Inc, Morris Plains, NJ]), and anti-
CD15 (LeuTech [Palatin Technologies, Princeton, NJ]) (20).  Each of these 
antigranulocyte antibodies labeled with 99mTc were determined to allow the accurate 
delineation of infection and inflammation.  It was reasoned that since neutrophils increase 
the expression of CD15 antigens when they become activated, these compounds should 
increase the amount of specific binding around sites of infection and, as a consequence, 
enhance the efficacy of the radiopharmaceutical as a diagnostic test (21).  None of these 
compounds, however, were specific for infection only as was original hypothesized.  
After further investigation it appeared that the behavior of these antigranulocyte 
antibodies differed from that of radiolabeled WBCs.  In short, it appears that they did not 
accumulate in the lungs post-injection and their circulatory clearance differed from that 
of their in vitro WBC labeled counterparts.   
 Mozley et al. later showed that a transient leukopenia typically occurred 15-20 
min post-injection of the anti-CD15 antibody and recovered with a mild 
overcompensation in approximately one hour (21).  This transient leukopenia is not 
uncommon after injections of any compound and it has never been shown to be harmful 
or increase susceptibility to infections.  Since that time, it has become widely accepted 
that the behavior of these MoAbs is largely due to a localized hyperemia and an increased 
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vascular permeability which is non-specifically associated with both infection and 
inflammation.   
 
The future of radiolabeling WBCs using antibodies 
 The future of these compounds is uncertain due to the results of the few clinical 
trials that have been performed.  Also there is the theoretic and real possibility of a 
HAMA to any antibody that is made of nonhumanized protein.  Thus, the investigation of 
partial antibody fragments was undertaken to minimize these adverse reactions and to 
potentially avoid the transient pancytopenia that had been documented to occur with use 
of these agents (21). 
 
Respiratory Inflammation/Infection imaging 
 The literature and research surrounding respiratory infection imaging in nuclear 
medicine is relatively scarce.  This is not to say that the imaging of this organ system 
does not hold promise and the studies to date have not been encouraging.  As of now an 
important advance would be the development and general acceptance of an imaging 
modality that could quantitatively delineate lung inflammation, leading to the ability to 
monitor the therapeutic response in such diverse conditions as pneumonia, acute 
respiratory distress syndrome, cystic fibrosis, and Chronic Obstructive Pulmonary 
Disease (COPD). 
 Chen et al. have suggested that PET should be considered the most accurate 
quantitative radionuclide imaging method currently available for imaging pulmonary 
inflammation (22).  They were also able to show a positive correlation between the rate 
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of 18F-FDG uptake in lung field and the amount of neutrophils present in broncho-
alveolar lavage fluid in patients with cystic fibrosis, suggesting this may be a useful 
adjunct to monitoring inflammatory burden (23).  Another study conducted by Chen et 
al., performed in healthy volunteers, also showed that the inflammatory response to low-
dose endotoxin in a single lung segment can be visualized and quantified by imaging with 
FDG PET (24).   FDG PET has also shown promise in delineating inflammation resulting 
from bleomycin induced pneumonitis.  Bleomycin is commonly used in the treatment of 
Hodgkin’s lymphoma and bleomycin induced pneumonitis is a common cause of 
morbidity and even mortality resulting from treatment.  A case report of a 47 year old 
woman receiving treatment utilized FDG PET to distinguish resolution of disease 
activity, even in the presence of residual pulmonary scarring (25). 
 In patients with lobar pneumonia, an increase in 18F-FDG uptake was evident 
which was not so in the case of patients having brochiectasis.  In addition, neutrophil 
accumulation at the site of the lesion was evident with 111In-leukocytes (26).  In a study 
published in 2005, Mahfouz et al. examined the value of FDG PET in diagnosing 
infections in a population affected with multiple myeloma.  Ninety-nine of the one-
hundred and sixty-five infections identified were in the respiratory tract.  The results of 
this study determined that FDG PET imaging (whether for cancer staging or infection 
work-up) contributed to the overall patient management by 24-28% depending on the 
indication (infection vs. staging) (27).  While PET seems promising for respiratory 
infection imaging, this study was performed on a unique patient population that made any 
focal lung uptake unlikely to be due to malignancy.   Therefore, perhaps the clinical 
 15 
utility of FDG PET in diagnosing respiratory infections lies in certain specific sub-groups 
of patients where infection is suspected and malignancy highly unlikely. 
The diagnosis of a pulmonary lesion seen on plain film or CT typically raises the 
question of infection (acute or chronic) which can be a difficult one to answer.  However, 
the lack of clinical trials in respiratory infection imaging makes CT scanning and biopsy 
a necessity in a symptomatic patient in order to answer this question.  With the increasing 
awareness of radiation dosages and discomfort associated with biopsy, it would be 
extremely beneficial to continue research in this area, especially with some of the newer, 
postulated infection-specific agents.  This could negate biopsy or at the very least reduce 
patient anxiety and possibly decrease the necessity of high-resolution CT scanning. 
 
Abdominal Inflammation/Infection Imaging 
Inflammatory Disorders 
The area of abdominal inflammation imaging centers on the imaging of 
Inflammatory Bowel Disease (IBD).  IBD comes in two well described forms.  The first, 
ulcerative colitis (UC) typically is limited to the colon, sparing the small bowel and anus. 
Lesions are confined to the bowel mucosa, and they typically extend from a primary site 
rather than patches of inflammation.  The other entity, Crohn’s Disease (CD), can affect 
the entire length of the bowel, primarily displays skip lesions, and shows transmural 
inflammation on histopathology. More importantly, distinguishing the diagnosis between 
CD and UC is crucial, since therapeutic options differ greatly. 
 In the past, there were no general guidelines as to which of the many available 
tests was the best to use in a given clinical situation.  In 2005, Annovazzi et al. conducted 
a meta-analysis of peer reviewed articles published between 1984 and 2004 describing 
 16 
the use of nuclear medicine for the study of inflammatory bowel disorders, appendicitis 
and vascular graft infections (28). 
The main modalities used for IBD imaging are scintigraphy with autologous 
white blood cells, labeled with 111In-oxine or 99mTc-HMPAO.  These should be 
considered as the studies of choice in acute phases of disease, since endoscopic and 
barium studies are contraindicated.  For this indication, Annovazzi et al. analyzed a total 
of 4388 patients from 49 different studies (Table 2).  Their results revealed that for 
imaging IBD, alternative nuclear medicine techniques (scintigraphy with MoAbs and 
human polyclonal immunoglobulins) should be used only when a 99mTc-HMPAO WBC 
scan was not available, because of their lower overall sensitivity. However, these scans 
should be used to address specific questions, as ultrasound and barium studies have their 
clinical role as well.  That is, a labeled WBC scan should only be considered when 
radiological and/or endoscopic techniques are inconclusive (28).  Another specific 
indication is for determining recurrences on pre-anastomotic loops.   In this case, WBC 
uptake can be classified semi-quantitatively comparing the activity to that of iliac crest, 
liver and or spleen (28). 
 
<<TABLE 2>> 
 
Infectious Abdominal Disorders 
 Appendicitis is a very common disorder accounting for more than 1 out of 100 
emergency room visits and affecting nearly all age groups.  However, it has been shown 
that 30% of appendicitis presentations are misdiagnosed leading to the patient being 
discharged from the hospital with an erroneous diagnosis (29).  Moreover, the percentage 
of appendectomy where the appendix is normal is around 16%.  This is particularly true 
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for atypical clinical manifestations, or in certain populations, such as young children, 
pregnant women and elderly patients (28). 
 Annovazzi et al. reviewed data from a total of 1548 patients from 24 different 
papers.  The results of their analysis revealed that many nuclear medicine techniques 
show a high diagnostic accuracy: 99mTc-HMPAO, 111In-oxine WBCs, 99mTc-HIG, 99mTc-
MoAbs and can be indistinctly used (Table 3).   All agents showed good sensitivity and 
specificity.   However, this paper was published before the question arose as to certain 
complications resulting from the usage of these MoAbs, as these agents are no longer 
available for use in the US.  This leaves only WBC labeling as a viable option, with the 
caveat of having a significant delay in time to diagnosis, again highlighting the need for 
the development of more effective in vivo WBC labeling techniques.  It appears that at 
this time the role of nuclear medicine in appendiceal infection imaging (at least in the 
US) is not substantial. 
 The advent of PET/CT also shows promise for the future use of 18F-FDG to detect 
abdominal infections and allow for greater anatomic localization, leading to better 
diagnostic confidence.  Figure 2 demonstrates a right psoas muscle abscess found on 
FDG PET imaging.  The greater confidence achieved in localizing the infection played an 
important role in determining the management of this particular patient.   FDG PET has 
been shown to have an overall sensitivity of 90% in detecting abdominal and pelvic 
abscesses, bacterial colitis, diverticulitis, and infected vascular grafts (27, 30-32).  
Unfortunately, large scale studies in this area are lacking, and only time will tell if this 
agent can outperform 111In or 99mTc labeled WBCs.   
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Interestingly, a study conducted by Ingui et al. in 2007, suggests that the use of 
software fusing Single Photon Emission Computerized Tomography (SPECT) with CT is 
superior over traditional side-by-side SPECT and CT for 111In-labeled-WBCs or 67Ga 
Citrate scans.  The authors reported that a greater confidence was achieved in 71% of 
cases and the fused images altered interpretations in almost half of the studies examined 
(33).   In a comparison of SPECT/CT vs. traditional SPECT in general, Roach et al. 
found that final reports were significantly different in 26% patients compared to the 
reporting with planar/SPECT alone (34). 
 It is clear that we have only begun to scratch the surface of the many uses of 
PET/CT in delineating abdominal infections.  Given PET’s superior spatial resolution and 
anatomic localization when fused with CT, we may begin to see a gradual increase in the 
usage of FDG PET in detecting both known and suspected abdominal infections.  
Appendicitis is only one common illness that stands to benefit from FDG PET.  There are 
numerous other abdominal infections such as gastroenteritis, colitis, cholecystitis, 
pyogenic abscesses, prostatitis, cystitis, pyelonephritis, and gynecologic infections that 
may stand to benefit from this imaging modality.  With further research and clinical trials 
we can begin to better delineate the true extent of FDG PET or other positron emitting 
infection agents’ clinical utility. 
<<TABLE 3>> 
 
 
CNS Inflammation/Infection Imaging  
 The literature on CNS inflammation and infection imaging is relatively scarce at 
this point in time.  There have been very few clinical studies performed and most articles 
are case reports or involve only a small cohort of patients.  One such study evaluated the 
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use of dynamic SPECT with 99mTc-ethyl cysteinate dimer (99mTc-ECD) in 9 patients 
suspected of having herpes simplex viral encephalitis (HSVE) or other types of viral 
encephalitis.  It is thought that 99mTc-ECD SPECT is able to more accurately detect subtle 
focal changes in uptake because of a superior contrast to background ratio of activity in 
white matter.  The authors’ results showed that dynamic SPECT findings were positive in 
patients with HSVE and negative in those with non-HSVE.  It was reasoned that HSV 
primarily damages endothelial cells of the capillaries of the brain, leading to the higher 
focal uptake whereas other viruses may damage neurons more directly, with less vascular 
involvement (35). 
 An increasing amount of research has been performed on PET imaging techniques 
and their usefulness in CNS infection imaging.  One article looked at the imaging 
characteristics of PET in a patient with a known tuberculous brain abscess.  The 
possibility of a tuberculous brain abscess should be considered when 18F-FDG 
accumulates at the periphery of a ring-enhancing lesion in a chronically ill or 
immunocompromised patient (36).   This paper, however, only looked at a single patient 
and it has been previously suggested that any type of neoplastic or non-neoplastic lesion 
could produce this pattern of enhancement in the immunocompromised patients (37). 
 The development of the tracer O-(2-[18F]fluoroethyl)-]L-tyrosine (18F-FET) has 
been reported to allow tumor recurrence to be distinguished from radiation-induced 
changes in cases of suspected recurrent high and low grade gliomas, and it was also 
postulated that it would better able to differentiate neoplastic vs. non-neoplastic ring-
enhancing lesions.  A recent study however, concluded that 18F-FET PET has limited 
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specificity in distinguishing between neoplastic and non-neoplastic ring-enhancing 
intracerebral lesions thus making biopsy and histologic confirmation necessary (37). 
 A study performed in 2006 by Falagas et al., looked at the utility of 99mTc-
ciprofloxacin in diagnosing suspected spinal infections due to other tracers’ lack of 
sensitivity in this area.  The results of that preliminary study suggested that scintigraphy 
with 99mTc-ciprofloxacin may be useful in the diagnosis of active spinal infections (38).  
However, the authors’ also suggest that its usefulness in this particular area stems from 
this agents’ ability to distinguish between bacterial and sterile inflammation.  It should be 
noted that no controls were used in this study and since the time of publication it has been 
shown that 99mTc-ciprofloxacin is more likely a nonspecific indicator of inflammation 
than an infection specific agent. 
 In the inflammatory imaging spectrum of CNS imaging is the possibility of FDG 
PET usage to aid in diagnosing paraneoplastic neurological syndrome (PNS).  In the 
patient with PNS, brain FDG PET and brain Magnetic Resonance Imaging (MRI) are 
both complementary to each other, and frequently, abnormalities noted on FDG PET 
images can provide additional information which is clinically significant (39).  In a 
review of four different published articles, the authors also found that in the setting of 
paraneoplastic cerebellar degeneration, FDG PET generally reveals cerebellar 
hypometabolism analogous to the cerebellar atrophy on MRI, but it also tends to show 
the abnormality more often than MRI (39).  These findings suggest that FDG PET may 
be a future tool for the initial workup of a patient with PNS having either a known or 
unknown malignancy. 
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Postoperative Infections 
 The diagnosis of a postoperative infection is often a difficult one to make 
clinically.  Imaging can play a crucial role in helping to rule in or out the presence of 
infection.  Often times the decision still becomes a difficult one due to post operative 
inflammation and healing.  This difficulty increases even more so in the presence of 
orthopedic devices.  Consequently, bone, WBC and 67Ga scanning, as well as CT and 
MRI, are of limited use in this setting.  In aging adults, the problem of delay in 
diagnosing postoperative infections is even worse since the clinical manifestations in this 
population are frequently atypical.    
 A study performed in 2003 evaluated the utility of 99mTc-ciprofloxacin in 
diagnosing infections in postoperative spinal surgery patients.  In the case of 
postoperative spinal patients, WBC scanning is of limited use, but the low normal bone 
marrow uptake of 99mTc-ciprofloxacin along with its postulated bacterial specificity made 
it an ideal candidate to be evaluated in this setting (40).  In 2003, a study published by De 
Winter et al., found that of 49 postoperative spinal surgery patients, 99mTc-ciprofloxacin 
SPECT is up to 81% sensitive in evaluating infections in the postoperative spine, when 
operations performed less than 6 months prior were excluded. Not surprisingly, 
sensitivity was much higher for SPECT than for planar imaging (40). 
 FDG PET has also been suggested as a means for evaluating postoperative 
infections.  A 2005 study evaluated the utility of FDG PET in assessing postoperative 
infections in a rabbit model.  Comparisons were made between noninfected rabbits and 
rabbits in which infection with S. aureas was initiated at the time of surgery.  The results 
of this study found that SUV comparisons from the surgical site could not be used to 
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distinguish between the infected and uninfected groups until day 15.  However, visual 
analysis of scans revealed a significant difference between the infected and uninfected 
groups as early as day 8 (41).  These findings suggest that FDG PET may have more 
utility in postoperative infection imaging than was originally thought. 
 Another study from 2002, evaluated the sensitivity and specificity of various tests 
in diagnosing postoperative abdominal infections.  Thirty-three patients undergoing 
colorectal surgery and aged over 60 years were enrolled in the study. All patients 
underwent a gallium scan and C- Reactive Protein, WBC and endoscopic examinations.  
Of the four diagnostic modalities used, 67Ga scan had the highest overall diagnostic 
accuracy (90.9%) while the WBC test had the lowest sensitivity (60.6%) (42).This study 
just reiterates the importance of establishing a better means of postoperative infection 
imaging. 
 The advent of PET and SPECT imaging along with CT hybridization allows for 
much greater accuracy and confidence in diagnosis.  These modalities combined with 
newer infection imaging agents suggest that the future of postoperative infection imaging 
is bright.  Unfortunately, to date, only limited clinical trials have been done on a small 
number of agents.  If we are to properly advance the field of postoperative infection 
imaging, much larger and more numerous trials are needed to best compare each agents 
pros and cons, and develop a widely accepted, working algorithm.   
 
Modern Uses for 18F-FDG PET 
Fever of Unknown Origin 
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Of all the newer agents in development, none has received as much attention as 
the use of FDG PET in detecting infection.  The widespread availability of this agent has 
made it a convenient choice for many different clinical situations, and case reports 
regarding its usage in certain specific situations are abundant. One situation that has 
received particular attention is the usage of FDG PET in patients with fever of unknown 
origin (FUO).  Fever of unknown origin in adults is defined as a temperature higher than 
38.3°C that lasts for greater than three weeks with no obvious source despite an 
appropriate investigation. The majority of cases of FUO are due to infections, 
malignancy, collagen vascular diseases, and autoimmune disorders.  Among these causes, 
infections account for the most cases of FUO, followed by malignancy and other non-
infectious inflammatory diseases. 
 An early prospective study performed by Meller et al. involving 20 consecutive 
patients compared the role of FDG PET imaging with that of 67Ga-SPECT in patients 
with FUO.  The authors reported a sensitivity of 81% and a specificity of 86% for FDG 
PET vs. a sensitivity and specificity of 67% and 78%, respectively, for 67Ga SPECT (30).  
At this time, however, there is no general consensus as to the role of FDG PET in cases 
of FUO.  Although FDG PET is certainly useful in the setting of FUO, well-designed 
prospective studies remain necessary to quantify the efficacy of FDG PET for the 
evaluation of FUO, as it may potentially become a first-line imaging technique for 
assessments of these patients (43). 
 A prospective multi-center study analyzing the value of FDG PET in 70 patients 
with FUO by Bleeker-Rovers and colleagues found that FDG PET contributed to 
determining the etiology in 30% of patients.  Interestingly, they also found that FDG PET 
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was not helpful in any patient with a normal erythrocyte sedimentation rate (ESR) and 
CRP.  These findings suggest that FDG PET should be strongly considered as an early 
diagnostic study in patients presenting with FUO with an elevated ESR or CRP (43, 44). 
 A more recent article from Bleeker-Rovers et al. nicely summarized the results of 
seven recent studies of FDG PET in patients with FUO (Table 4).  However, comparing 
one study to another is difficult due to the difference in study design, PET technique, 
time of imaging, and varying definitions of FUO (45, 46). 
FDG PET seems to be increasingly recognized as having utility in FUO and 
infection imaging as a whole.  While the search for an infection-specific agent continues, 
in patients with FUO, 18F-FDG can provide useful benefits.  Its ability to show areas of 
increased glucose utilization, allows for visualization of more than one etiology such as: 
infection, inflammatory disorders, malignancy, etc. 
 
<<TABLE 4>> 
 
Immunocompromised Infection Imaging 
 FDG PET can be a useful tool for diagnosing and managing infections even in the 
setting of severe neutropenia or lymphopenia (27).  In addition to this, FDG PET uptake 
has also been shown to correlate with the degree of HIV infection and increasing viral 
load (47).  We have already discussed the uses of PET in distinguishing between CNS 
infection and malignancy in patients with AIDS.  But in addition to this, there seems to 
be utility in all cases of inherited or acquired neutropenia. 
 For example, Gungor et al. sampled 43 patients born immunocompromised with 
chronic granulomatous disease (CGD) and compared FDG PET vs. CT in 22 and 19 
patients, respectively.  Their results showed that PET was able to exclude 59 lesions 
 25 
suspicious for active infection on CT and also reveal 49 infective lesions not seen on CT.  
These findings showed that whole body FDG PET can be used to screen for active 
infections in patients with CGD (48).  Another article from Depas et al. reported the 
clinical impact of PET/CT usage in immunocompromised neonates.  The authors suggest 
that, based on their findings, FDG PET should be considered in difficult cases of neonatal 
infection or in challenging diagnoses.  They also felt that PET/CT allows for more 
accurate staging and treatment monitoring of the in invasive infections of 
immunocompromised children (49). 
 
 
Promising Agents 
99mTc-labeled Interleukin-8 
 Interleukin 8 (IL-8) is a well known chemotactic cytokine that binds with a high 
affinity to receptors expressed on activated neutrophils.  A 99mTc-labeled IL-8 preparation 
was developed with hydrazinonicotinamide (HYNIC) as a chelating agent was shown to 
have some promising characteristics in initial animal model experiments (49).  This led to 
the development of the first clinical trial in humans performed by Bleeker-Rovers et al., 
on 20 patients suspected of having localized infections.  In 10 of 12 patients with 
infections, 99mTc-IL-8 localized the infection at 4 h after injection. In 1 patient with 
vertebral osteomyelitis and in 1 patient with an infected knee prosthesis, 99mTc-IL-8 
scintigraphy results were false (50).  Of the 8 patients determined to have noninfectious 
disorders, no focal accumulation of 99mTc-IL-8 was noted.  In addition, focal 
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accumulation to sites of infection occurred as early as 4 hours after injection.  No 
significant side effects were noted (50). 
 Due to the positive results and lack of significant side effects, this appears to be a 
promising new agent.  However, it is not yet reasonable to assume this agent is infection 
specific.  Larger scale trials must be performed to determine what role, if any, this agent 
will play in the future of infection imaging. 
 
fMLP 
 N-formyl products, such as N-formyl-methionyl-leucyl-phenylalanine (fMLF or 
fMLP) are formed via the cleavage of bacterial and mitochondrial proteins.  These 
products are among the first identified potent chemoattractants for activated leukocytes 
The first studies on these compounds were carried out in the early 1980’s (51,52). 
Early studies using these agents showed localization of infection within 1 hour 
post-injection.  However, even a dose as low as 10 ng/kg of the agent induced a transient 
leukopenia.  One study using 99mTc-HYNIC-fMLFK in rabbits with intramuscular 
abscesses showed visualization of the infected foci at 2 hours post-injection.  The 
authors’ demonstrated a moderate abscess-to-normal-tissue ratio at 4 hours post-injection. 
This study again noted a transient leukopenia (65% reduction) that occurred 30 minutes 
after injection (53,54).  
 
Future Outlook 
 Overall, the area of infection imaging in nuclear medicine is one rich with 
ongoing research.  While an infection specific imaging agent is still lacking, the 
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development of one would greatly advance our ability to detect, localize, and quantify 
respiratory, abdominal, CNS, and post-operative infections.  It appears that the superior 
spatial resolution of PET combined with CT for better anatomic localization is gaining 
support as a more effective means of infection imaging, especially in those with FUO or 
nonfunctional immune systems.  Therefore, the hybridization of an infection specific 
radiopharmaceutical, imaged via SPECT or PET and combined with CT will pave the 
way for greater reliability and clinical utilization of these technologies in the evaluation 
of difficult patients.  
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Table 1.   
Strategies in infection imaging with specific tracers. 
Label leukocytes migrating to foci of infection 
• Direct labeling of leukocytes (ex vivo labeling) 
• Indirect labeling of leukocytes (in vivo labeling): 
• Antibody-antigen interactions: radiolabeled antigranulocyte monoclonal antibodies/antibody fragments 
• Binding to receptors on leukocytes 
• Radiolabeled chemotactic peptides: fMLP 
• Radiolabeled cytokines: IL-2, IL-8, PF- 4 
 
Target inflammatory mediators  
• Anti-E-selectin antibodies or anti-E-selectin Fab fragments 
 
Target locally present micro-organisms 
• Radiolabeled ciprofloxacin, other antibiotics 
• Radiolabeled antimicrobial peptides 
 
Target the increased metabolic activity of infected areas 
• 
18F-FDG PET 
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Table 2.   
Imaging modalities for imaging inflammatory bowel diseases.  Results of meta-analysis. 
Imaging Modality Patients Sensitivity 
(%) 
Specificity 
(%) 
Patients Accuracy 
(%) 
Patients 
 
PPV NPV 
 
111In-WBCs 
 
682 
 
87.97 
 
93.43 
 
651 
 
91.71 
 
374 
 
93.27 
 
80.06 
99mTc-WBCs 1427 88.36 91.54 1195 85.45 889 93.12 83.39 
99mTc-WBCs >3h 1459 90.69 84.94 1071 89.12 808 89.45 82.02 
99mTc / 111In-HIG 110 75.73 83.93 110 76.28 110 92.38 62.67 
Endoscopy 58 91.33 72.30 58 86.22 58 91.03 75.52 
Computed 
Tomography 
110 80.32 88.93 71 83.68 0 NA NA 
WBCs- white blood cells; HIG –Human Immunoglobulin; PPV – Positive Predictive Value;  
NPV- Negative Predictive Value; NA – Not Available 
Table Adapted from (28) 
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Table 3.   
Nuclear medicine modalities in the diagnosis of appendicitis: results of meta-analysis 
Imaging Modality Number of 
scans 
Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
PPV NPV 
111In-WBCs 128 89.53 95.01 92.97 90.97 93.65 
99mTc-WBCs <2h 224 93.83 92.06 92.41 85.60 96.51 
99mTc-WBCs <4h 572 92.86 88.00 89.29 88.69 92.20 
99mTc-MoAb 629 90.81 87.26 89.04 79.55 94.15 
WBCs- white blood cells; PPV – Positive Predictive Value; NPV- Negative Predictive Value; NA – Not Available 
Table Adapted from (28) 
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Table 4.   
Studies evaluating the value of FDG PET in patients with FUO. 
First Author Study Design 18F-FDG PET 
technique 
Results/Conclusions 
Meller et al.  15 Prospective (n=20)  
compared FDG PET 
and 67Ga citrate (n=18) 
Dual-headed 
coincidence camera 
FDG PET helpful in 55% 
PPV 92%, NPV 75% 
Bleeker-Rovers et al. 31 Retrospective (n=35) Full ring PET scanner FDG PET helpful in 37% 
PPV 87%, NPV 95% 
Bleeker-Rovers et al. 43 Prospective (n=70) Full ring PET scanner FDG PET helpful in 33% 
PPV 70%, NPV 92% 
PPV – Positive Predictive Value; NPV- Negative Predictive Value  
Table Adapted from (46) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 40 
Figure 1.   
Positive 67Ga scan in a patient diagnosed with PCP pneumonia 
 
Image courtesy of Dr. Kim & Dr. Intenzo, Department of Nuclear Medicine, Thomas Jefferson University 
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Figure 2.   
FDG PET scan demonstrating a right psoas muscle abscess. 
 
Image courtesy of Dr. Alavi & Dr. Wieger, Department of Radiology, University of Pennsylvania. 
 
 
 
 
 
 
